Amgen Inc vs. Immunovant, Inc. Common Stock
Amgen Inc and Immunovant, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| AMGN | IMVT | |
|---|---|---|
| Market Cap | $205.32 billion | $7.72 billion |
| Revenue (TTM) | $38.09 billion | — |
| Net Income (TTM) | $8.74 billion | — |
AMGN leads on 1 of 1 size & scale factors.
Valuation
| AMGN | IMVT | |
|---|---|---|
| P/E Ratio | 23.95 | — |
| Price / Book | 17.57 | — |
| Price / Sales | 5.39 | — |
AMGN and IMVT split the valuation factors evenly.
Profitability
| AMGN | IMVT | |
|---|---|---|
| Net Margin | 22.95% | — |
| Return on Equity | 74.80% | — |
AMGN and IMVT split the profitability factors evenly.
Dividend
| AMGN | IMVT | |
|---|---|---|
| Dividend Yield | 2.61% | — |
| Payout Ratio | 62.61 | — |
AMGN and IMVT split the dividend factors evenly.
Risk & Sentiment
| AMGN | IMVT | |
|---|---|---|
| Short Interest | 1.66% | 0.15% |
IMVT leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, IMVT overview, IMVT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.